Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
Dr. Ryan Saadi, Chairman and CEO of Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, has extended congratulations to Lynne Patton on her appointment as Deputy Assistant to the President and Director of Minority Outreach. Ms. Patton will join the Office of Public Liaison, focusing on building support among Blacks, Latinos, and Women.
Patton previously served as Regional Administrator for Federal Region II at HUD and Senior Advisor to Secretary Ben Carson, where she worked on housing reform and accountability. In her new role, she will lead outreach efforts to minority communities.
Dr. Saadi emphasized Tevogen Bio's commitment to supporting presidential initiatives for affordable medical innovation, stating that business success should contribute to societal prosperity.
Il Dr. Ryan Saadi, Presidente e CEO di Tevogen Bio (Nasdaq: TVGN), una biotech specializzata in immunoterapia clinica, ha esteso le sue congratulazioni a Lynne Patton per la sua nomina a Vice Assistente del Presidente e Direttore dell'Iniziativa per le Minoranze. La signora Patton entrerà nell'Ufficio delle Relazioni Pubbliche, concentrandosi sulla costruzione di supporto tra i neri, i latini e le donne.
In precedenza, Patton ha ricoperto il ruolo di Amministratrice regionale per la Regione Federale II presso l'HUD e Consigliera senior per il Segretario Ben Carson, dove ha lavorato su riforme abitative e responsabilità. Nel suo nuovo ruolo, guiderà gli sforzi di sensibilizzazione verso le comunità minoritarie.
Il Dr. Saadi ha sottolineato l'impegno di Tevogen Bio nel sostenere le iniziative presidenziali per un'innovazione medica accessibile, affermando che il successo imprenditoriale dovrebbe contribuire alla prosperità sociale.
El Dr. Ryan Saadi, Presidente y CEO de Tevogen Bio (Nasdaq: TVGN), una biotecnológica especializada en inmunoterapia en etapa clínica, ha extendido sus felicitaciones a Lynne Patton por su nombramiento como Asistente Adjunta del Presidente y Directora de Alcance a Minorías. La Sra. Patton se unirá a la Oficina de Relaciones Públicas, centrándose en construir apoyo entre la comunidad negra, latina y mujeres.
Patton se desempeñó anteriormente como Administradora Regional para la Región II Federal en HUD y Asesora Senior del Secretario Ben Carson, donde trabajó en la reforma de vivienda y la rendición de cuentas. En su nuevo papel, liderará los esfuerzos de divulgación hacia las comunidades minoritarias.
El Dr. Saadi enfatizó el compromiso de Tevogen Bio con el apoyo a las iniciativas presidenciales para una innovación médica asequible, afirmando que el éxito empresarial debería contribuir a la prosperidad social.
라이언 사아디 박사, 테보젠 바이오(Nasdaq: TVGN)의 회장 겸 CEO는 린 패튼이 대통령 보좌관 겸 소수자 outreach 담당 이사로 임명된 것에 대해 축하의 뜻을 전했습니다. 패튼 씨는 공공 연락 사무국에 합류하여 흑인, 라틴계 및 여성 커뮤니티의 지원을 구축하는 데 집중할 것입니다.
패튼은 이전에 HUD의 연방 제2 지역 관리자 및 벤 카슨 장관의 수석 고문으로 재임하면서 주택 개혁 및 책임성에 대한 업무를 수행했습니다. 그녀는 새로운 역할에서 소수자 커뮤니티를 위한 outreach 노력을 이끌 것입니다.
사아디 박사는 테보젠 바이오가 저렴한 의료 혁신을 위한 대통령의 이니셔티브를 지원하겠다고 강조하며, 비즈니스 성공이 사회적 번영에 기여해야 한다고 덧붙였습니다.
Le Dr. Ryan Saadi, Président et CEO de Tevogen Bio (Nasdaq: TVGN), une biotechnologie spécialisée en immunothérapie clinique, a félicité Lynne Patton pour sa nomination en tant qu'Assistante Adjointe du Président et Directrice de l'Initiative pour les Minorités. Mme Patton rejoindra le Bureau des Relations Publiques et se concentrera sur le soutien aux communautés noires, latinos et aux femmes.
Avant cela, Patton a été Administratrice Régionale pour la Région II Fédérale au HUD et Conseillère Senior auprès du Secrétaire Ben Carson, où elle a travaillé sur la réforme du logement et la responsabilité. Dans son nouveau rôle, elle dirigera les efforts de sensibilisation auprès des communautés minoritaires.
Le Dr. Saadi a souligné l'engagement de Tevogen Bio à soutenir les initiatives présidentielles pour une innovation médicale accessible, en affirmant que le succès commercial devrait contribuer à la prospérité de la société.
Dr. Ryan Saadi, Vorsitzender und CEO von Tevogen Bio (Nasdaq: TVGN), einem biotechnologischen Unternehmen, das auf klinische Immuntherapien spezialisiert ist, hat Lynne Patton zu ihrer Ernennung als stellvertretende Assistentin des Präsidenten und Direktorin für Minderheitenangelegenheiten gratuliert. Frau Patton wird dem Büro für öffentliche Beziehungen beitreten und sich darauf konzentrieren, die Unterstützung unter Schwarzen, Latinos und Frauen auszubauen.
Patton war zuvor als regionale Administratorin für die Bundesregion II beim HUD und als Senior Advisor für Minister Ben Carson tätig, wo sie an Wohnungsreformen und Rechenschaftspflicht arbeitete. In ihrer neuen Rolle wird sie die Outreach-Bemühungen für Minderheitengemeinschaften leiten.
Dr. Saadi betonte das Engagement von Tevogen Bio zur Unterstützung präsidialer Initiativen für erschwingliche medizinische Innovation und erklärte, dass der wirtschaftliche Erfolg zur gesellschaftlichen Wohlfahrt beitragen sollte.
- None.
- None.
WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Patton on being appointed Deputy Assistant to the President and Director of Minority Outreach.
Ms. Patton will join the Office of Public Liaison and will be responsible for ensuring that President Trump continues to build upon his Election Day support from Blacks, Latinos and Women. Ms. Patton has been one of the Trump family’s longest serving and most trusted aides. Previously, Ms. Patton was the Regional Administrator for Federal Region II at the U.S. Department of Housing and Urban Development (HUD) and Senior Advisor to Secretary Ben Carson. At HUD, Ms. Patton worked tirelessly to bring accountability, reform and results to some of the most challenging housing issues facing our country. From championing the rights of underserved communities to exposing corruption and mismanagement within public housing systems, Lynne consistently fought for fairness and opportunity, earning her the bipartisan respect of industry peers and local elected officials alike. Lynne’s deep connection to the issues affecting minority communities combined with her remarkable interpersonal skills, makes her the ideal person to lead this critical outreach effort.
“Being appointed Deputy Assistant to the President and Director of Minority Outreach is both an honor and an opportunity to continue my bipartisan efforts on behalf of the White House in supporting important issues impacting all Americans with a focus on underserved communities, both rural and urban,” commented Ms. Patton.
Dr. Saadi added, “Business success can be an unattainable concept unless it contributes to societal prosperity. As a pioneering AI biotech, we are committed to supporting the President’s initiative to advance affordable medical innovation.”
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c2966b9-ee9f-4aa9-810c-11b44d470dfa
FAQ
What is Tevogen Bio's (TVGN) stance on affordable medical innovation?
How does Lynne Patton's appointment impact Tevogen Bio (TVGN)?
What is Tevogen Bio's (TVGN) current market position?
What recent leadership changes have occurred at Tevogen Bio (TVGN)?
